爱博特公司于2026年3月23日完成了对Exact Sciences的230亿美元收购,将癌症查工具添加到其诊断组合中. Abbott completes $23B acquisition of Exact Sciences on March 23, 2026, adding cancer screening tools to its diagnostics portfolio.

雅培将在监管部门批准后,于2026年3月23日完成对麦迪逊公司Exact Sciences的230亿美元收购. Abbott will complete its $23 billion acquisition of Madison-based Exact Sciences on March 23, 2026, following regulatory approval. 这笔交易扩大了阿伯特的诊断产品组合, 提供精确科学查癌症工具, 包括Cologuard和Oncotype DX. The deal expands Abbott’s diagnostics portfolio with Exact Sciences’ cancer screening tools, including Cologuard and Oncotype DX. 艾博特公司的首席执行官罗伯特·福德表示,此举加强了其在诊断领域的领导地位,并改善了医疗保健的获取. Abbott’s CEO Robert Ford said the move strengthens its leadership in diagnostics and improves access to healthcare. 虽然最近裁员了200名工人, 但Exact Sciences将保留其麦迪逊总部和业务. Exact Sciences will retain its Madison headquarters and operations, though it recently laid off 200 workers. 公司每年为威斯康星州的经济贡献数十亿美元, 并继续成为该州健康创新生态系统中的重要参与者. The company contributes billions annually to Wisconsin’s economy and remains a key player in the state’s health innovation ecosystem.